Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company with a strong focus on lung disease and oncology, and its news flow reflects that specialization. Company updates frequently cover performance of its lung diagnostics business, including revenue trends, test volumes, and reimbursement developments for its Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance.
Investors and clinicians following BDSX news can expect regular financial and operating results releases, where Biodesix reports revenue from Lung Diagnostics and Development Services, discusses gross margins, and comments on measures such as Adjusted EBITDA. These announcements often describe factors influencing growth, such as increased test adoption, payer coverage, and expansion into clinical settings like pulmonology and primary care.
Biodesix also issues news about its Development Services activities and partnerships with biopharmaceutical and life sciences companies. Recent items include an expanded agreement to develop and clinically validate Droplet Digital PCR high complexity assays on Bio-Rad platforms, as well as availability of an ultra-sensitive ESR1 assay for biopharma customers and clinical use in advanced breast cancer.
Another recurring theme in BDSX news is scientific and medical conference participation. The company highlights poster presentations, workshops, and corporate events at meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. These stories showcase new clinical utility data for Nodify Lung tests, health economic analyses of pulmonary nodule management, and research on molecular diagnostic technologies such as NGS, ddPCR, and mass spectrometry.
In addition, Biodesix reports on corporate and capital markets developments, including reverse stock split actions and Nasdaq listing compliance updates, as well as investor conference participation. For users tracking BDSX, this news page provides a centralized view of operational performance, scientific progress, collaborations, and key corporate milestones over time.
Biodesix reported Q2 2022 financial results showing a 52% increase in core lung diagnostic revenue, totaling $7.3 million, compared to the same period in 2021. The overall revenue was $11.0 million, an 8% decline due to decreased COVID-19 testing. The company has received Medicare coverage for its Nodify CDT® test, enhancing long-term margins. Operating expenses rose 21% to $18.6 million, with a net loss of $15.8 million. Biodesix reaffirms its 2022 revenue outlook of $37.5 million to $39.5 million.
Biodesix, a prominent diagnostic solutions company specializing in lung diseases, announced that CEO Scott Hutton will present at the Canaccord Genuity 42nd Annual Growth Conference, scheduled for August 10, 2022, at 3:00 PM ET in Boston. The event will be available for live streaming on Biodesix's website. The company is known for its innovative diagnostic tests, including the Nodify Lung® nodule risk assessment and IQLung™ strategies for lung cancer, aiming to expedite treatment decisions. Biodesix also launched COVID-19 diagnostic tests, responding to the ongoing pandemic.
Biodesix, Inc. (BDSX) has announced promising results from a retrospective analysis of its VeriStrat proteomic test presented by Dr. Young Kwang Chae at the IASLC 2022 World Conference on Lung Cancer in Vienna. This analysis focused on patients with advanced-stage non-small cell lung cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICIs) and highlighted that the test effectively predicts Progression Free Survival (PFS) and Overall Survival (OS) in patients with low or negative PD-L1 expression.
Biodesix, a diagnostic solutions company focusing on lung disease, will release its Q2 financial results on August 4, 2022, before trading begins. A conference call will take place at 8:00 a.m. ET for a financial discussion and business update. The company's non-invasive tests, such as Nodify Lung and IQLung, aim to improve lung disease diagnostics and treatment decisions. Biodesix utilizes advanced AI for diagnostic solutions and has expanded its testing portfolio in response to the COVID-19 pandemic.
Biodesix, Inc. (Nasdaq: BDSX) announced Medicare coverage for its Nodify CDT® lung nodule test, a significant milestone for lung nodule management. This test is part of Biodesix’s Nodify Lung® Nodule Risk Assessment strategy, which also includes the Nodify XL2® test. Both tests assist physicians in determining whether lung nodules are likely malignant or benign. With all five blood-based diagnostic tests now covered by Medicare, Biodesix aims to enhance patient access and expedite treatment decisions, crucial for lung cancer care.
Biodesix, a leader in diagnostic solutions for lung disease, announced the development of a novel minimal residual disease (MRD) test in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad. This initiative, part of a master sponsored research agreement, aims to enhance cancer treatment through advanced diagnostic tests. The project will leverage Biodesix's capabilities in genomics, proteomics, and AI, focusing initially on a highly sensitive MRD test for solid tumors using the ddPCR™ platform. CEO Scott Hutton emphasized this project as a significant milestone.
Biodesix, a diagnostic solutions company focused on lung disease, announced that CEO Scott Hutton will present at the 42nd Annual William Blair Growth Stock Conference on June 8, 2022, at 9:20 a.m. CT in Chicago, IL. The company encourages investors to schedule meetings with management during the event. A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days. Biodesix specializes in comprehensive blood-based tests to assess lung disease risks, significantly enhancing patient care.
Biodesix, a data-driven diagnostic solutions company focused on lung disease, announced that CEO Scott Hutton will present at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The pre-recorded presentation will be available on-demand starting May 24 at 7:00 AM ET through the company's website. Biodesix specializes in non-invasive tests for lung diseases, utilizing multi-omics and AI technology. Their innovative tests, such as Nodify XL2 and IQLung, support critical decision-making in lung cancer treatment.
Biodesix, Inc. (BDSX) reveals clinical utility data for its Nodify XL2 Risk Assessment Test at the American Thoracic Society (ATS) 2022 Conference, held May 13-18 in San Francisco. The study shows that the test effectively reduces unnecessary imaging and procedures for lung nodules with a malignancy probability of ≤ 50%, presenting significant advantages in clinical management. Additionally, the ALTITUDE trial will be discussed, evaluating the clinical utility of the Nodify XL2. These presentations reinforce Biodesix's commitment to advancing lung disease diagnostics.
Biodesix (BDSX) announced Q1 2022 results with total revenue of $6.5 million, a 77% decrease year-over-year, influenced by lower COVID-19 diagnostic testing. However, core lung diagnostic revenue rose 17% to $4.6 million, driven by the Nodify test. The company added $27.4 million in debt and equity funding in Q2 2022, enhancing financial stability. Operating expenses increased 10% to $17.8 million, leading to a net loss of $15.6 million, a 124% increase. The outlook for 2022 remains positive, expecting total revenue between $37.5 and $39.5 million.